

***In vitro* Characterization of 3-Chloro-4-hydroxybenzoic Acid Building Block Formation in Ambigol Biosynthesis**

I Dewa Made Kresna,^{a,b} Luis Linares-Otoya,^{a,b} Tobias Milzarek,^c Elke R. Duell,^{c,d} Mahsa Mir Moseni,^{e,f} Ute Mettal,^{a,b} Gabriele M. König,^e Tobias A. M. Gulder^{c,g} and Till F. Schäberle^{a,b,*}

Supporting Information

Table S1. Conserved motifs of DAHP synthase Ab7.

Organism	Motif			Accession Number
	DxxHxN	KPRT	xGxR	
<i>S. cerevisiae</i>	IDY SHGNS 285	KPRT 117	I GAR 180	GI: 48425087
<i>C. albicans</i>	VDC SHGNS 283	KPRT 108	I GAR 170	GI: 3647668
<i>E. coli</i>	IDF SHANS 271	KPRT 102	I GAR 165	GI: 12932715
<i>H. influenzae</i>	VDF SHANS 279	KPRT 109	I GAR 172	GI: 950411
<i>S. typhimurium</i>	VDC SHGNS 272	KPRT 103	I GAR 166	GI: 1252280
<i>F. ambigua</i>	IDC SHGNS 273	KPRT 103	I GAR 166	This study

Table S2. Multiple sequence alignment of the metal binding amino acid (AA) residues of DAHP synthase Ab7.

Organism	AA residue binding to the metal ion				Accession Number
	C	H	E	D	
<i>S. cerevisiae</i>	GPCSI 78	SHGN 284	IESN 318	TDAC 344	GI: 48425087
<i>C. albicans</i>	GPCSI 72	SHGN 282	IESN 316	TDAC 345	GI: 3647668
<i>E. coli</i>	GPCSI 63	SHAN 270	VESH 304	TDAC 328	GI: 12932715
<i>H. influenzae</i>	GPCSI 70	SHAN 278	VESH 312	TDAC 336	GI: 950411
<i>S. typhimurium</i>	GPCSI 64	SHGN 271	IESN 305	TDAC 330	GI: 1252280
<i>F. ambigua</i>	GPCSI 64	SHGN 272	LESN 306	TDKC 331	This study

Table S3. Influence of metal salt addition on the enzymatic activity of Ab7. One unit of enzyme activity is defined as the consumption of 1 μmol PEP per minute.

Metal Salt	Activity Unit
MnCl ₂	7.5 $\pm$ 0.5
MgCl ₂	7.0 $\pm$ 1.0
ZnCl ₂	7.5 $\pm$ 0.5
CuSO ₄	2.0 $\pm$ 1.0
CdSO ₄	5.0 $\pm$ 1.0
EDTA	0.0 $\pm$ 0.0

Table S4. The results of the Fre assay for measurement of UV absorbance at 340 nm. Consumption of NADH by Fre was calculated by the difference of $A_{340\text{ nm}}^1$ minus $A_{340\text{ nm}}^2$.

Reaction in HEPES Buffer (a)

Incubation time (min)	$A_{340\text{ nm}}^1$ (Control)	$A_{340\text{ nm}}^2$ (with Fre)	NADH consumption by Fre $A_{340\text{ nm}}^1 - A_{340\text{ nm}}^2$
5	0,582	0,322	0,26
30	0,505	0,038	0,467
60	0,431	0,035	0,396
120	0,317	0,035	0,282
180	0,254	0,034	0,22

Reaction in Phosphate Buffer (b)

Incubation time (min)	$A_{340\text{ nm}}^1$ (Control)	$A_{340\text{ nm}}^2$ (with Fre)	NADH consumption by Fre $A_{340\text{ nm}}^1 - A_{340\text{ nm}}^2$
5	1,332	1,105	0,227
30	1,269	0,602	0,667
60	1,203	0,455	0,748
120	1,102	0,422	0,68
180	1,021	0,411	0,61

Reaction in Tris-Cl Buffer (c)

Incubation time (min)	$A_{340\text{ nm}}^1$ (Control)	$A_{340\text{ nm}}^2$ (with Fre)	NADH consumption by Fre $A_{340\text{ nm}}^1 - A_{340\text{ nm}}^2$
5	2,169	2,029	0,14
30	1,995	1,58	0,415
60	1,912	1,519	0,393
120	1,775	1,394	0,381
180	1,688	1,308	0,38




Figure S1. SDS page analysis of Ab7 after purification. FT, flow through; W1 and W2, washing steps (with 30 and 50 mM imidazole, respectively); E1 – E5, elution fractions (100- 350 mM imidazole); M, marker (kDa). The arrow indicates the band corresponding to Ab7. Elution fractions 1 – 5 were pooled, concentrated and redissolved in Tris HCl buffer (pH 7). The protein concentration was determined spectrophotometrically to be around 1 mg/mL, using Thermo Scientific NanoDrop.




Figure S2. Effect of (a) incubation temperature and (b) pH on Ab7 activity.




Figure S3. Lineweaver-Burk plot of Ab7 with various E4P concentrations (0.025 - 1 mM) and a constant concentration of PEP. Using Graf Pad Prism 5, kinetic constants of Ab7 were determined according to double-reciprocal curves. A double-reciprocal plot of Ab7 was calculated against the substrate concentration. The concentration of PEP was always preserved at 80 μM while the concentration of E4P was varied between 0.025 and 1 mM. The maximum velocity achieved by the system, at saturating substrate concentrations (v_{max}), was determined to be 0.3725 ± 0.083 (U/mg^{-1}) and the obtained K_m and k_{cat} values were shown to be 0.6993 ± 0.3746 mM and 0.0281 ± 0.063 s^{-1} , respectively.




Figure S4. Purification of Ab1 as analyzed by SDS-Page.




Figure S5. Purification of Ab10 as analyzed by SDS-Page.




Figure S6. Purification of Fre as analyzed by SDS-Page.




Figure S7. LCMS data for the in vitro assay using 4-HBA (**7**) as the substrate of Ab1, Ab10, or both. The assay was conducted (a) only with Ab10, (b) only with Ab1, (c) with Ab1 and Ab10. The (d) standard of 2,4-dichlorophenol (**6**), and the (e) standard of 3-Cl-4-HBA (**11**) served for comparison. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides for (d) and (e) close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Displayed in green are the extracted ion chromatograms (EIC) of the $[M-H]^-$ peak of **11** (theoretical $m/z = 170.9843$). Shown in blue are the extracted ion chromatograms of the $[M-H]^-$ peak of **6** (theoretical $m/z = 160.9555$). As apparent from the images, neither substance **6** nor **11** could be detected.




Figure S8. Purification of (a) Ab6, (b) Ab8, and (c) Ab9 (C-PCP) as analyzed by SDS-Page.




Figure S9. LCMS data of the Ab6 *in vitro* assay. The assay was performed (a) without ATP, (b) without CoA, (c) without the substrate 4-HBA (**7**), (d) without Ab6, and as (e) complete reaction. For comparison a (f) standard of **7** was used. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. The red chromatogram in (f) illustrates the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of the substrate standard **7** (m/z theoretical = 139.0395). The blue chromatogram shows the EIC of the $[M+H]^+$ peak of the product 4-HBA-CoA (**13**) (m/z theoretical = 888.1436).




Figure S10. LCMS analysis of the control experiment for the *in vitro* carrier protein assay. For this control trial the substrate 4-HBA (**7**) was incubated with cysteamine in the presence or absence of Ab6. The (a) standard of substrate **7** served for comparison. The assay was performed (b) without Ab6, and (c) with Ab6. Mass spectra were measured in positive mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Displayed in green are the extracted ion chromatograms (EIC) of the $[M+H]^+$ peak of the substrate **7**. The blue chromatogram shows the EIC of the $[M+H]^+$ peak of the product “4-HBA-cysteamine” (**15**) (theoretical m/z = 273.0726). As apparent from the images, product **15** could be detected in sample (c).




Figure S11. LCMS analysis of the Ab8 and Ab9 (C-PCP) carrier protein *in vitro* assay. The assay was performed in the presence of Ab6 using 4-HBA (**7**) as substrate. Prior to cysteamine treatment, Ab8 and Ab9 (C-PCP) were purified by HPLC. Mass spectra were measured in positive mode. In the assay either (a) Ab8 or, (b) Ab9 (C-PCP) served as a carrier protein. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Displayed in blue are the extracted ion chromatograms (EIC) of the $[M+H]^+$ peak of the product “4-HBA-cystamine” (**15**) (theoretical $m/z = 273.0726$). As apparent from the images, product **15** could be detected only when Ab8 was used as a carrier protein.

CLUSTAL O(1.2.4) multiple sequence alignment

```

Ab10 -----
Mcnd MKTVEFLAYLNSLQINLWAENDKLRYSRSPQGVMTPELLGKLKERKEQLIALLRQKAEDLG 60
Apdc MKTVNFLSHLNDLGINVWVENDKLRYSRSPKGVIIPELLQELKERKEELIAFLRQQAEDLN 60
AerJ MKTVEFLSDNLHLGVTIWMEGDKLRYSRSPQGVMTDDLLEQLKEHKEELIVLLREQADNFS 60

Ab10 MKNIYDVAICGSGLAGLTLARQLKLKMPDISVVVLDRLARPLPEAGFKVGESEVEVGAFY 60
Mcnd EAEVYDVVICGGLAGLTLARQLKLQKNISVIVLDKIARPLPEASFVGESEVEVGAFY 120
Apdc QAETYDVVICGGLAGLTLARQLKLQKNMAIAVLDKMSGLSPEASFVGESEVEVGAFY 120
AerJ SETDYDVAICGGLAGLTLGRQLKLKQPNLSVVVLDKMARPLPEAGFKVGESEVEVGAFY 120
      ***.***.*****.*****:   :::  ***:::   ***.*****:*****
      GxGxxG motif

Ab10 LAHIVQLEDYLEKQHLHKLGLRFLGDTKGPFHKRPEIGLSKYHFPNSYQLDRGKLENDL 120
Mcnd LANTLQLTDYFEEQHLVKLGLRFFNNSATNFQDRPELGLSEFHLPSYQIDRGKLENDL 180
Apdc LANTLQLTDYFEEQHLVKLGLRFFNNSATNFQERPELGLSEFHAPNSYQIDRGKLENDL 180
AerJ LANTLQLTDYFDHQHLPKLGLRFFKQETEFHKRPELGLSEFHAPKSYQIDRGKLENDL 180
      **:  **:  **:  **:  **:  **:  **:  **:  **:  **:  **:  **:  **:  **:  **:
      *:  *:  *:  *:  *:  *:  *:  *:  *:  *:  *:  *:  *:  *:  *:

Ab10 RSINTEAGVELLEGCLVKDIELGDP--QQLHQIIYTQEN--NKATQAIQARWVDSMGYRR 177
Mcnd RAFNVEAGVELRENCLVNEIELAVGLQQHHKIVYTQDKGDHKKTNVIQARWVDAMGRRR 240
Apdc RQFNMEAGVELREGCLVNEIALAEGQQHHKVYVYTGQDGDNRKNKI IKARWVDAMGRRR 240
AerJ RQFNIEAGIDLKENC SVKDIEFAEGLQQQHKI IYTGSGANQKTHCIKSRWVDAMGRRR 240
      *  :  *  ***:  *  *  *  *:  *  :  *  *  *:  *  *  *  *  *  *  *  *  *
      *  :  *  ***:  *  *  *  *:  *  :  *  *  *:  *  *  *  *  *  *  *  *  *

Ab10 FLQRKLGLAKPKNSQFSAVWFRVEGRFDVSDFPSTEIEWHERVPHNNRYYSTNHLCEG 237
Mcnd FLQKKLGLDKPNNAQFGAVWFRVEGRFDISDFVPSSEKWHNRVPNKNRYYSTNHLCEG 300
Apdc FLQRKLGLDKPNDNFAGVWFRVNGRFDIGDFVPSSEKWHNRVPNKNRYYSTNHLCEG 300
AerJ FIQKKLGLAKPNHNYS AVWFRVEGRFDVSNFVPASEEKWHRRVPNNRYYSTNHLCEG 300
      *:  *:  ***  **:  :  :  *****:  *****:  *:  *:  *:  *:  *:  *:  *:  *:  *:
      *:  *:  ***  **:  :  :  *****:  *****:  *:  *:  *:  *:  *:  *:  *:  *:  *:

Ab10 YWVWLIPLPSTGYTSIGIVTNEEIHFPFGTYHTYEKAFQWLEKHEPVVAFHLKSNPPVDFMK 297
Mcnd YWVWTIPLPSTGHTSIGIVARQDIHPLKTYNYELAYQWLQKNEPTLAFHLADKQPEDFRK 360
Apdc YWVWTIPLPSTGHTSIGIVARQDIHPLKNYNYELAYQWLQKNEPVLACHLKDKEPEDFRK 360
AerJ YWVWLIPLPSTGYTSIGIVARQDIHPLKNYHNYELAFQWLRENEPVLAAHLEGKSPEDFRK 360
      ****  *****:  *****:  :  :  *:  :  *  *  *:  *  *:  *  *  *  *  *  *  *
      WxWxIP motif

Ab10 IPQYSYSSNQVFSINRWACVGVAGVFADPFYSPGTDLIGFGNSLITQMVELDRENKLTPE 357
Mcnd MPKYSYSSKQVFSYNRWACVGEAGTVDPDFYSPGTDNIGFGNSLTTQLITLDLEGKLTQE 420
Apdc MPKYSYSSKQVFSNWRACVGEAGTFDPDFYSPGTDNIGFGNSLTTQLIALDLEDKLTKE 420
AerJ MPKYSYSSKQVFSFNWRACVGEAGLFPDFYSPGSDSIGFGNSLTTQMIELDLKGQLTPE 420
      :  *:  *****:  *****  *****  *  *  *  *****:  *  *****  *:  *  :  :  *  *  *

Ab10 IVNEANRFLITYNESVTSNIHNAYLCFGNETVMVMKYIWDVLSAWAFSAPMMFNSLFLDS 417
Mcnd KVKDANHFYLSYSDGVTLNIQNAYNCLGNMVMATKFIWDTLSGWTFSGLMMFNSIYLDQ 480
Apdc KVEDANYFYISYSDGVTLNIQNAYNCLGNIVMATKFIWDTLSGWTFSGLMMFNSIFLDQ 480
AerJ RVDDANHFYLTYHDLTFNIQNSYCNMGNGIVMATKMIWDTLAGWTFGCLMMFNSIFLDP 480
      *  :  *  *  *  :  :  *  :  :  *  *:  *:  *  *:  *  *  *  *  *  *  *  *  *  *  *
      *  :  *  *  *  :  :  *  :  :  *  *:  *:  *  *:  *  *  *  *  *  *  *  *  *

Ab10 DKRAKVRKGTGQFFLLAQRMNQLFRDWAVQSQRRTSFEFIDYLQIPFVRELARNLKTNK 477
Mcnd EFRTKVQQISSKFFPLSYRMQQLFKDWANQSLHRVNFEFIDYLAIPFVEELRSRNLRYNQ 540
Apdc DFRTRVQEINSKFFPLSYRMQQLFRDWANKSLNRVNFEFIDYLAIPFVDELRTNRLKSNK 540
AerJ ELKMKVQQINAEFFPLSYRIQQLFRDWANQSLGRVSFEFIDYLAIPFVNELRTNRLQSNK 540
      :  :  :  *:  :  :  *  *  *:  *:  *****:  *  *  *  *****  *****  *:  *:  *:  *:  *:

Ab10 TEQELIDDHLASIKLFEELAQVIFLLALEDTMPEKSADFPSPVWLNWVVSLDDKRWEID 537
Mcnd TESEIIENYLSSLKLLEEVAQVMFHLALEDIMPEMLPKVSSNSWLNWAWAISLNASKWESD 600
Apdc TKSEIIENYLSSLKLLEEVAQVMFHLALEDTMPDMLSKVNSNSWLNWAWAISLDISKWEAD 600

```

```

AerJ  TEAEIIEAYRASLKLLEEFQVIFQIALEDTSPELLTKINEHPWLNAWAISLDASKWETD 600
      *: *: *: : :*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:*:
      .. . *****.:*:*: :.:** *

Ab10  GLFRPTSKPRDLRPMMEQLWQNIHFRAADDRDSSLITA 574
McnD  GLFAPKSEPRNLDLIKQQLWEAIGK----- 625
ApdC  GLFTPKSEPRNLNLIKQQLWEAIGK----- 625
AerJ  GLFSPKNEPRNLHSIKKQYLEAINR----- 625
      *** *..:*:*: : :* : *

```

Figure S12. Alignment of Ab10 with McnD, ApdC and AerJ using CLUSTALO (1.2.4) multiple sequence alignment (<https://www.uniprot.org/align/>). GxGxxG and WxWxIP motifs are highlighted in bold letters.




Figure S13. LCMS analysis of the Ab10 *in vitro* assay. For comparison a (a) standard of the product 3-Cl-4-HBA-SNAC (**17**), and a (b) standard of substrate 4-HBA-SNAC (**16**) were used. The assay itself was performed (c) without Fre, (d) without Ab10, and as (e) complete reaction. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Displayed in red are the extracted ion chromatograms (EIC) of the $[M+Na]^+$ of the substrate **16** (m/z theoretical = 262.0508). The green chromatogram shows the EIC to $[M+Na]^+$ of the product **17** (m/z theoretical = 296.0119).




Figure S14. LCMS analysis of the *in vitro* assay of Ab10 using bromide as the halogen source for investigating Ab10 substrate specificity. The assay was performed as a (a) complete reaction, and (b) without Ab10. A (c) standard of the substrate 4-HBA-SNAC (**16**) was used for comparison. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) are shown in blue, red and green, respectively. The purple chromatogram in (c) illustrates the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of the substrate **16** (m/z theoretical = 240.0694). Black chromatograms in “a”, “b” and “c” show the EIC of the $[M+H]^+$ peak of the product 3-Br-4-HBA-SNAC **18** (m/z theoretical = 339.9619).




Figure S15. LCMS analysis of the *in vitro* assay of Ab10 using iodide as the halogen source. Mass spectra were measured in positive mode. For comparison the (a) standard of the substrate 4-HBA-SNAC (**16**) was used. The assay was performed (b) without Ab10, and as a (c) complete reaction. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Red chromatograms show the extracted ion chromatogram (EIC) of the $[M+Na]^+$ peak of **16** (theoretical $m/z = 262.0508$). Blue chromatograms show the EIC of the $[M+H]^+$, $[M+Na]^+$, and $[M+K]^+$ peaks (theoretical $m/z = 365.9655$, 387.9457 , 403.9214 respectively) of the expected product 3-I-4-HBA-SNAC (**20**). As apparent from the images, no peak of the expected product **20** could be observed.




Figure S16. LCMS analysis of the *in vitro* assay of the C domain from Ab9 using 4-HBA-SNAC (**16**) as the substrate. The assay was performed using (a) only Ab9 (C-PCP) without substrate **16**, and as (b) complete reaction. Mass spectra were measured in positive mode. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of the product “4-HBA-cystamine” (**15**). As apparent from the images, product **15** could not be detected, neither in the control sample (a) nor in the complete reaction (b).




Figure S17. LCMS analysis of the *in vitro* assay of the C domain from Ab9 using 3-Cl-4-HBA-SNAC (**17**) as the substrate. The assay was performed using (a, b) only Ab9 (C-PCP) without substrate **17**, and as a (c, d) complete reaction. Mass spectra were measured in positive mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of the product “3-Cl-4-HBA-cystamine” **19** (theoretical $m/z = 307.0336$). As apparent from the images, product **19** could only be detected in the complete reaction sample.




Figure S18. Purification of Ab9 (PCP-TE) as analyzed by SDS-Page.











Figure S19. LCMS analysis of the (a) standard 3-Cl-4-HBA-SNAC (**17**) in comparison to the (b) standard of 3-Cl-4-HBA (**11**). Mass spectra were measured in positive mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Red chromatograms show the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of **11** (theoretical $m/z = 173.0000$). Blue chromatograms show the EIC of the $[M+H]^+$ peak of **17** (theoretical $m/z = 274.0299$). As apparent from the images, there is a contamination of **11** in the standard of **17**.













Figure S20. LCMS analysis of the control reaction (without Ab9 (PCP-TE)) of the time dependent Ab9 (PCP-TE) *in vitro* assay. For comparison a (a) standard of substrate 3-Cl-4-HBA-SNAC (**17**) and a (g) standard of the product 3-Cl-4-HBA (**11**) were used. The reactions (b), (c), (d), (e), (f) were incubated for 0, 5, 30, 60 min and 24 hours respectively. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Green chromatograms show the extracted ion chromatogram (EIC) of the $[M-H]^-$ peak of the substrate **17** (m/z theoretical = 272.0148). Red chromatograms show the EIC of the $[M-H]^-$ peak of the product **11** (m/z theoretical = 170.9848).






Figure S21. LCMS analysis of the complete Ab9 (PCP-TE) treated reaction of the time dependent Ab9 (PCP-TE) *in vitro* assay. For comparison a (a) standard of substrate 3-Cl-4-HBA-SNAC (**17**) and a (g) standard of the product 3-Cl-4-HBA (**11**) were used. The reactions (b), (c), (d), (e), (f) were incubated for 0, 5, 30, 60 min and 24 hours respectively. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Green chromatograms show the extracted ion chromatogram (EIC) of the [M-H]⁻ peak of the substrate **17** (m/z theoretical = 272.0148). Red chromatograms show the EIC of the [M-H]⁻ peak of the product **11** (m/z theoretical = 170.9848).




Figure S22. LCMS analysis of Ab9 (PCP-TE) substrate specificity experiment with respect to the substrate 4-HBA-SNAC (**16**). For comparison a (a) standard of the substrate **16**, and a (d) standard of the product 4-HBA (**7**) were used. The assay was carried out (b) without Ab9 (PCP-TE) (control), and as a (c) complete reaction. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Green chromatograms show the extracted ion chromatogram (EIC) of the $[M+H]^+$ peak of the substrate **16** (m/z theoretical = 240.0694). Red chromatograms show the EIC of the $[M+H]^+$ peak of the product **7** (m/z theoretical = 139.0395).




Figure S23. LCMS data of the *in vitro* investigation of Ab6 substrate specificity with respect to the substrate 3-Cl-4-HBA (**11**). The assay was carried out (a) without ATP, (b) without CoA, (c) without substrate **11**, (d) without Ab6, and as (e) complete reaction. Mass spectra were measured in positive mode. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M+H]^+$ and $[M+Na]^+$ peaks of 3-Cl-4-HBA-CoA (theoretical $m/z = 922.1046$ and 944.0866 respectively). As apparent from the EIC, the expected product could not be detected.

```

Ab1  MSNLPKSTKVLVVGGGPAGTTAATLLAREGFDITLLEREVFPRYHIGESLLPSSLK-VLD 59
CmlS  ----MTRSKVAIIGGGPAGSVAGLTLLHKLGHDTVITYERSAFPYRVGESLLPGTMS-ILN 55
CndH  MSTRPEVFDLIVGGGPAGSTLASFVAMRGHRVLLLEREAFFRHQIGESLLPATVHGICA 60
      .: :*:***.*:. . : * . : : **..***:::*****.: :

Ab1  LLGVRDKIDAHGQFYKPGGHHYHWGDEHWDLNFSDSL-----GNITHSYQVRRDEFDKLLL 114
CmlS  RLGLQEKIDAQNYVKKPSATFLWGQDQAPWTFSAAPKVAPWVFDHAVQVKREEFDKLLL 115
CndH  MLGLTDEMKRAGFPPIKRGGTFRWGKEPEPWTFGFTRHPDDPY--GFAYQVERARFDDMLL 118
      **: :*: .: * . : *: .*. .: **.* .*:**

Ab1  DHAKSQGVKVFVDGIGVSSLSFENERPKSAIWSQTNDKNHTGEISFDLIDATGRYGLMAN 174
CmlS  DEARSRGITVHEETPVTDDVLSDPD--RVVLT-VRRGGESVTVESDFVIDAGSGGPI-S 171
CndH  RNSERKGVDRERHEVIDVLFEGERAAGVRYR--NTEGVELMAHARFIVDASGNRTRV-S 175
      .:. :*: * : * .: . . . . . *:** * :

Ab1  HHLKNREYHDFQNVAVIWGYWKNADRLDNGREGAIIIESLKDGLWGLPLHDTISVGLV 234
CmlS  RKLGVQRQYDEFYRNFVWSYFKLDPFEGDLKGTYSITFEDGWVWMIPKDDLYSVGLV 231
CndH  QAVGERVYSRFFQNVALYGYFENGKRLPAPRQGNILSAAFQDGFWYIPLSDTLTSGAV 235
      : : * * .:*.***.:* . : :* :*:**.* ** : * * * *

Ab1  VHKTIIYKEKRSKSLKDIYLEGIAESLDLKRLLPEGEL-----ASEVRSEQDYSYAADSFA 289
CmlS  VDRSKSAEVREQGADAFYSSTLAKCAKAMDILGGAEQ-----VDEVRIQDWSYDTEVFS 286
CndH  VSREAAEAI-KDGHEAALLRYIDRCPIIKEYLAPATRVTTGDYGEIRIRKDYSCNTSFW 294
      * : . . . . : .. * . .*: * :** *

Ab1  GQGYFMIGDAACFLDPLLSTGVHLATFSGLLSAASLASVIRNHITTEEQAISFFERTYKQA 349
CmlS  ADRFFLCGDAACFTDPLFSQGVHLASQSASVAAAIDRI TRHGDEKDAVHAWYNRTYREA 346
CndH  KNGMALVGDAACFVDPVFSSGVHLATYSALLVARAINTCLAGEMSEQRCFEFERRRYRE 354
      : : * * * * * *: * * * * : : :* *:.

Ab1  YLRMLAMVSAFYEN--SKKESYFWQAQQLTKTRQSNEDKEKLHQMFLNVVSG--MEDMS 404
CmlS  YEYHQFLASFYTFASFTPEDFWRKRITESDDDLTRKKW----FESLAGNGPEDPS 402
CndH  YGNFYQFLVAFYDMN--QDTSYFWSARKIINTEERAN-----EAFVRLIAGRSNLDEP 406
      * . : : ** . : * * : : : : . . :*: *

Ab1  DAEENSEELFLEL-----SERLRENWS-----LRHKQT----ANDL----- 436
CmlS  GTV-----ASF-----RDRASTMIA-----IGRHQRP-ELSDDF----- 430
CndH  VFQSVAKDFFTEREGFGAWFGGLVTSMAKDGGLMVGEATDATESTGFAPENFMQGFT 466
      . : : : : :

Ab1  -----DQTE--EEKLRASNQFVSRNLNGLFSLSK---ESAVEGLYIVTTPQLGLV 480
CmlS  -----SEAELNPARVRWISDLTKRLNSITRFKWTGGKAVLKQHYRVEPIGFRLE 479
CndH  REITELQHLAMFGEDRGPEPLWSGGGLVPSRDGLAWAVESGEDAAG----- 512
      : . :. :. :.

Ab1  QVN----- 483
CmlS  QREVLANGEGLDMAQYPMDEARQIFQDLAEEEFQYKTLVKRLGAVGRQELSTQIVVRLM 539
CndH  -----

Ab1  -----
CmlS  EAGLLTGYPDAGQGEKVFVQGRLLHFGGVGVEYEV 571
CndH  -----

```

Figure S24. Alignment of Ab1 against CmlS and CndH with GxGxxG and WxWxIP motifs being highlighted in bold red letters. BLASTp alignment of Ab1 against the database shows, that almost all of the 100 first hits are tryptophan 7-halogenases or NAD(P)/FAD-dependent oxidoreductases with the highest percentage of identity being 72.52%. However, none of those hits is so far experimentally characterized. A refined BLASTp search using the pdb database and including only experimentally characterized enzymes, revealed the first two hits to be CmlS and CndH. However, as can be concluded from the query cover, both of them do not share AA sequence in their C-terminal region. Differences in the C-terminal region of Flavin-dependent halogenases (FDH) are the origin of their regio- and substrate specificity, as described by the characterization of PyrH^[1]. The N-terminus usually displays the region which forms the FAD binding site^[2].




Figure S25. LCMS analysis of the *in vitro* assay using 3-Cl-4-HBA (**11**) as the substrate of Ab1. The assay was carried out (a) without Fre, as (b) complete reaction, (c) without Ab1. The (d) standard of substrate **11**, and the (e) standard of the product 2,4-dichlorophenol (**6**) served for comparison. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Red chromatograms show the extracted ion chromatogram (EIC) of the $[M-H]^-$ peak of **11** (theoretical $m/z = 170.9843$). Blue chromatograms show the EIC of the $[M-H]^-$ peak of **6** (theoretical $m/z = 160.9555$). As apparent from the images, the expected product **6** could not be observed.




Figure S26. LCMS analysis of the *in vitro* assay using 3-Cl-4-HBA-SNAC (**17**) as the substrate of Ab1 in the presence of Ab9 (PCP-TE). The assay was carried out (a) without Ab1, as (b) complete reaction (with Ab1 and Ab9 (PCP-TE)), (c) without Fre, and (d) without Ab9 (PCP-TE). The (e) standard of 2,4-dichlorophenol (**6**), the (f) standard of 3-Cl-4-HBA (**11**), and the (g) standard of substrate **17** served for comparison. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M-H]^-$ peak of **6** (theoretical $m/z = 160.9555$). Green chromatograms show the EIC of the $[M-H]^-$ peak of **11** (theoretical $m/z = 170.9843$), while the red chromatograms display the EIC of the $[M-H]^-$ peak of **17** (theoretical $m/z = 272.0143$). The significant decrease of **17** and concomitant increase of **11** in the reactions (a)-(c) relative to (d) can be attributed to the activity of Ab9 (PCP-TE) which was not present in reaction (d). However, as apparent from the images, under various condition, the expected product **6** could not be observed.




Figure S27. LCMS analysis of the *in vitro* assay using 2-chlorophenol as the substrate of Ab1. For comparison a (a) standard of the product 2,4-dichlorophenol (**6**) was employed. The assay was carried out as (b) complete reaction, (c) without Fre, and (d) without Ab1. Mass spectra were measured in negative mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M-H]^-$ peak of **6** (theoretical $m/z = 160.9555$). As apparent from the images, the expected product **6** could not be detected.




Figure S28. Graphic representation of Table S5 showing NADH consumption (green line) by Fre in (a) Tris-Cl, (b) Phosphate, and (c) HEPES buffer. Without Fre, the absorption ($A_{340\text{ nm}}$) was decreasing over time, too. Therefore, it is likely that NADH naturally degraded over time. However, when Fre was present, the decrease of $A_{340\text{ nm}}$ was accelerated, indicating that NADH as substrate of Fre was consumed. According to our results, Fre is active in all buffers tested.




Figure S29. LCMS analysis of the *in vitro* assay of Ab10 in three different buffers. The utilized buffers were (a) Tris-Cl, (b) phosphate, and (c) HEPES, respectively. The (d) standard of the product 3-Cl-4-HBA-SNAC (**17**) and the (e) standard of the substrate 4-HBA-SNAC (**16**) served for comparison. Mass spectra were measured in positive mode. The upper part of the figure shows the respective chromatograms, while the lower part provides close-ups of the corresponding mass spectra. Base peak chromatograms (BPC) of each sample are shown in black. Blue chromatograms show the extracted ion chromatogram (EIC) of the $[M+Na]^+$ peak of **17** (theoretical $m/z = 296.0119$), while red chromatograms display the EIC of the $[M+H]^+$

peak of the substrate **16** (theoretical $m/z = 240.0689$). As shown in the images, the reaction product **17** was produced in comparable amounts in the three different buffers used (judging by the peak intensity), thus indicating that Ab10 works equally well in all three buffer systems.




Figure S30. ¹H spectrum of S-2-acetamidoethyl 4-hydroxybenzothioate (16).




Figure S31. ¹³C spectrum of S-2-acetamidoethyl 4-hydroxybenzothioate (16).




Figure S32. DEPT spectrum of *S*-2-acetamidoethyl 4-hydroxybenzothioate (**16**).




Figure S33. ¹H spectrum of S-2-acetamidoethyl 3-chloro-4-hydroxybenzothioate (**17**).




Figure S34. ¹³C spectrum of S-2-acetamidoethyl 3-chloro-4-hydroxybenzothioate (**17**).




Figure S35. DEPT spectrum of *S*-2-acetamidoethyl 3-chloro-4-hydroxybenzothioate (**17**).

References

- [1] X. Zhu, W. De Laurentis, K. Leang, J. Herrmann, K. Ihlefeld, K. H. van Pée, J. H. Naismith, *Journal of Molecular Biology*, 2009, 391, 74-85
- [2] K. Podzelinska, R. Latimer, A. Bhattacharya, L. C. Vining, D. L. Zechel, Z. Jia, *Journal of Molecular Biology*, 2010, 397, 316-331.